The group with increased expression of both HSPC111 and nuclear YAP1 showed poorer differentiation than the other groups (Table 2), suggesting that HSPC111+/nuclear YAP1+ GC patients manifested higher-grade malignancy. This evidence concerns the gene YAP1 and gastric cancer.